John R. Stuelpnagel net worth and biography

John Stuelpnagel Biography and Net Worth

John R. Stuelpnagel, D.V.M. has been Chairman of our board of directors since August 2013. In addition, Dr. Stuelpnagel co-founded and was Executive Chairman of Ariosa Diagnostics from October 2009 to January 2015 when that company was sold to Roche. He was also the Chairman of Sequenta from November 2010 to January 2015 when that company was merged with Adaptive Biotechnologies where he continued as a member of their board of directors from January 2015 to November 2017. Dr. Stuelpnagel is the Chairman of Fabric Genomics since August 2009, the Chairman of Inscripta since April 2017, the Chairman of Element Biosciences since September 2017, and a member of the board of directors for Encoded Therapeutics since May 2017. Previously, Dr. Stuelpnagel co-founded Illumina in 1998 where he worked until March 2009. Prior to Illumina, Dr. Stuelpnagel was an associate at CW Group from 1997 to 1998. Dr. Stuelpnagel received his B.S. in Biochemistry and his Doctorate in Veterinary Medicine from the University of California, Davis and his M.B.A. from the University of California, Los Angeles.

What is John R. Stuelpnagel's net worth?: The estimated net worth of John R. Stuelpnagel is at least $9.19 million as of June 5th, 2023. Mr. Stuelpnagel owns 333,736 shares of 10x Genomics stock worth more than $9,191,089 as of April 26th. This net worth estimate does not reflect any other assets that Mr. Stuelpnagel may own. Learn More about John R. Stuelpnagel's net worth.
How do I contact John R. Stuelpnagel?: The corporate mailing address for Mr. Stuelpnagel and other 10x Genomics executives is 6230 STONERIDGE MALL ROAD, PLEASANTON CA, 94588. 10x Genomics can also be reached via phone at 925-401-7300 and via email at [email protected]. Learn More on John R. Stuelpnagel's contact information.
Has John R. Stuelpnagel been buying or selling shares of 10x Genomics?: John R. Stuelpnagel has not been actively trading shares of 10x Genomics over the course of the past ninety days. Most recently, John R. Stuelpnagel sold 10,000 shares of the business's stock in a transaction on Monday, June 5th. The shares were sold at an average price of $54.89, for a transaction totalling $548,900.00. Following the completion of the sale, the director now directly owns 333,736 shares of the company's stock, valued at $18,318,769.04. Learn More on John R. Stuelpnagel's trading history.
Who are 10x Genomics' active insiders?: 10x Genomics' insider roster includes Bradford Crutchfield (Insider), Benjamin Hindson (Insider), Sridhar Kosaraju (Director), Mathai Mammen (Director), Justin McAnear (CFO), Serge Saxonov (CEO), John Stuelpnagel (Director), and James Wilbur (Insider). Learn More on 10x Genomics' active insiders.
Are insiders buying or selling shares of 10x Genomics?: During the last year, insiders at the sold shares 29 times. They sold a total of 182,020 shares worth more than $9,613,552.06. The most recent insider tranaction occured on March, 4th when CEO Serge Saxonov sold 4,660 shares worth more than $205,040.00. Insiders at 10x Genomics own 10.7% of the company. Learn More about insider trades at 10x Genomics.
Information on this page was last updated on 3/4/2024.

John R. Stuelpnagel Insider Trading History at 10x Genomics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/5/2023	Sell	10,000	$54.89	$548,900.00	333,736
12/1/2021	Sell	5,000	$151.16	$755,800.00
11/16/2021	Sell	5,000	$158.83	$794,150.00
11/1/2021	Sell	5,000	$163.51	$817,550.00
10/18/2021	Sell	5,000	$150.67	$753,350.00
9/16/2021	Sell	5,000	$156.33	$781,650.00
9/1/2021	Sell	5,000	$177.48	$887,400.00
8/16/2021	Sell	5,000	$159.56	$797,800.00	386,313
7/16/2021	Sell	5,000	$170.31	$851,550.00	396,116
6/17/2021	Sell	5,000	$199.38	$996,900.00	406,516
5/17/2021	Sell	7,500	$141.57	$1,061,775.00	420,491
5/3/2021	Sell	7,500	$191.81	$1,438,575.00	427,891
4/16/2021	Sell	7,500	$192.61	$1,444,575.00	434,891
4/1/2021	Sell	7,500	$184.53	$1,383,975.00	443,250
3/17/2021	Sell	7,500	$169.36	$1,270,200.00	450,291
2/16/2021	Sell	7,500	$193.00	$1,447,500.00	465,591
2/1/2021	Sell	7,500	$176.05	$1,320,375.00	473,091
1/19/2021	Sell	7,500	$178.76	$1,340,700.00	479,591
1/4/2021	Sell	7,500	$139.86	$1,048,950.00	487,191
12/16/2020	Sell	7,500	$148.21	$1,111,575.00	494,890
12/1/2020	Sell	7,500	$151.23	$1,134,225.00	501,391
11/17/2020	Sell	7,500	$135.98	$1,019,850.00	510,591
11/2/2020	Sell	7,500	$136.36	$1,022,700.00	516,163
10/16/2020	Sell	7,500	$164.26	$1,231,950.00	521,492
9/16/2020	Sell	7,500	$121.63	$912,225.00	540,591
9/1/2020	Sell	7,500	$113.92	$854,400.00	546,489
8/17/2020	Sell	7,500	$104.67	$785,025.00	555,191
8/3/2020	Sell	7,500	$99.34	$745,050.00	558,823
7/16/2020	Sell	7,500	$88.86	$666,450.00	567,217
7/1/2020	Sell	7,500	$87.58	$656,850.00	574,987
6/17/2020	Sell	7,500	$89.14	$668,550.00	582,196

John R. Stuelpnagel Buying and Selling Activity at 10x Genomics

10x Genomics Company Overview

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Today's Range

Now: $27.59

$26.60

$27.94

50 Day Range

MA: $38.12

$26.90

$48.45

2 Week Range

Now: $27.59

$26.30

$63.57

Volume

1,337,407 shs

Average Volume

1,471,818 shs

Market Capitalization

$3.29 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.9

Better than Bitcoin? The Biotech Stock with 46,751% Potential

From Behind the Markets | Ad

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>